Chief Editor

Dr Abdulrazak Abyad
Abyad Medical Center & Middle East Longevity Institute
Azmi Street, Abdo Center,

PO BOX 618
Tripoli
Lebanon


Phone:
(961) 6-443684
Fax:
(961) 6-443685
Email:
aabyad@cyberia.net.lb

Editorial Board

Current issues

Past issues

Submission of articles

Advertising detail


Publishers
medi+WORLD International
572 Burwood Road
Hawthorn
Australia

Ph: +61 3 9819 1224
Fax: +61 3 9819 3269

 

Meet the Team

BIOGRAPHY


Jeffery L. Cummings MD,

Jeffrey L. Cummings, M.D. was born in Wyoming.  He graduated from the University of Wyoming with high honors and attended medical school at the University of Washington in Seattle. Following medical school, Dr. Cummings completed a rotating internship at Hartford Hospital (a Yale affiliate) in Hartford, Connecticut.  After internship, he went to Boston University in Boston, Massachusetts for his Neurology residency and Fellowship in Behavioral Neurology.  Fellowship training in the United States was followed by a Research Fellowship in Neuropathology and Neuropsychiatry at the National Hospital for Nervous Diseases, Queen Square, London, England.  Dr. Cummings joined the UCLA faculty in 1980 and progressed to the rank of Professor in 1990.  In 1996 he was made The Augustus S. Rose Professor of Neurology.  He is also Professor of Psychiatry and Biobehavioral Sciences at UCLA. Dr. Cummings is the founder and director of the UCLA Alzheimer’s Disease Center. The Center has an active clinical trials program and fosters imaging, genetics, clinical and neuroscience research. Dr. Cummings is Director of the UCLA Behavioral Neuroscience and Dementia Research Fellowship.  Many of the approximately 40 fellows that he has trained currently hold leadership positions in dementia programs throughout the United States and the world.   Dr. Cummings’ interests embrace clinical trials and the development of new treatments for neurodegenerative disorders and other neurological diseases.  He is the founder and director of the Deane F. Johnson Center for Neurotherapeutics at UCLA.  He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association.  Dr. Cummings has authored or edited 19 books and over 400 peer reviewed papers.  He has broad interests in dementing disorders, neuropsychiatry, neurotherapeutics, and the interface of neuroscience and society. 

His current titles include:
The Augustus S. Rose Professor of Neurology
Professor of Psychiatry and Biobehavioral Sciences
Director, UCLA Alzheimer's Disease Center
Director, Deane F. Johnson Center for Neurotherapeutics
Executive Vice Chair, Department of Neurology
David Geffen School of Medicine at UCLA


Professor Hervé ALLAIN, MD, Rennes University, Rennes, FRANCE

Hervé Allain was born in St Brieuc (France) in 1950, married in 1973 (4 children) and obtained his degrees of medecine and physiology at the University of Rennes I (France). His training and diploma in Pharmacology were obtained in Paris after several stays abroad in clinical pharmacology (Rochester NY, USA ; Berlin, Germany ; Bombay, India ; Stockholm, Sweden). He was professor of Medecine in 1982 specialized both in Neurology and Pharmacology. He obtained the direction of the Department of Experimental and Clinical Pharmacology in 1992 at the Rennes Medical School. His main involvement in scientific research deals with central nervous system (CNS) pharmacology including psychotropics and compounds specifically used in Neurology. He published 500 papers and book chapters ; 175 references appear on Medline (Pubmed). The frontiers between psychiatry and neurology are particularly studied in his department with a clear focus on cognitive functions and their modulation by CNS drugs. The gap between neurosciences (ie : neurotransmitters and their receptors) and efficacy or side-effects in humans represents a deal for his team. H. Allain teaches at different levels of pharmacy and medicine in Rennes University ; he created 7 years ago a teaching course on the web :

www.med.univ-rennes1.fr/etud/pharmaco.
The main involvement at the present time, is the participation in the discovery in new compounds in the treatment of Alzheimer's Disease and other Dementia. Involvement in regulatory affairs and Drug Agencies (AFFSaPS, EMEA) is part on the activities.

July 2004
Volume 1,
Issue 1



Table of Contents


Home

From the Editor: Geriatrics in the Middle East


Meet the team

Determinants of prescribing for the elderly in primary health care

Aging mechanisms: from genetics to daily functioning

The use of ambulatory blood pressure monitoring in a hypertension clinic

A study on physical, social and mental problems of the elderly in District 13 of Tehran

Epidemiology of Self-Dependence among Kuwaiti Elderly Population of Abdullah Al-Salem Area

Active Aging: the whole society benefits

Clinical quiz - Palliative Care